Gene therapy in systemic lupus erythematosus

Preclinical studies have provided proof of concept for the feasibility and efficacy of gene therapy in human systemic lupus erythematosus (SLE). Successful efforts include gene constructs that alter the expression of cytokines or limit the cognate interaction of immune cells. Other efforts may include gene modified cell transfer such as autologous B cells transfected with tolerogenic constructs or T cells in which specific molecular aberrations have been corrected.